Rapid improvement of disseminated intravascular coagulation by donor leukocyte infusions in a patient with promyelocytic crisis of chronic myelogenous leukemia after reduced-intensity stem cell transplantation from an HLA 2-antigen-mismatched mother.
Donor leukocyte infusion (DLI) is recognized as effective therapy for relapse after stem cell transplantation in patients with chronic myelogenous leukemia (CML). However, the clinical efficacy of DLI in the advanced phase of CML or other types of leukemia has not been clearly defined because of its varying degree of success. We describe a 22-year-old male patient with promyelocytic crisis of CML who had a relapse after peripheral blood stem cell transplantation, under reduced-intensity conditioning, from his HLA 2-antigen-mismatched mother. Complete hematologic remission was obtained after transplantation. However, a relapse that occurred on day 66 posttransplantion was characterized by an increase in number of leukemic promyelocytes with simultaneous exacerbation of disseminated intravascular coagulation (DIC). The patient received DLI containing 1 x 10(7)/kg CD3+ cells on day 73. Because rapid improvement of DIC paralleled the decrease in leukemic cells and because it was observed soon after DLI and before the development of acute graft-versus-host disease (GVHD), we hypothesized that leukemia-specific cells other than natural killer cells or cytotoxic T-cells unrelated to GVHD played a role in the graft-versus-leukemia effect observed in our patient. In addition, this may be the first report of effective correction of DIC by DLI after stem cell transplantation.
Matsue
Kosei
K
Division of Hematology/Oncology, Kameda General Hospital, Chiba, Japan. koseim@dc4.so-net.ne.jp
Yamada
Konagi
K
Takeuchi
Masami
M
Tabayashi
Takayuki
T
D000328:Adult; D001752:Blast Crisis / Q000473:pathology; D004211:Disseminated Intravascular Coagulation / Q000628:therapy*; D006098:Granulocytes / Q000473:pathology; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D000949:Histocompatibility Antigens Class II / Q000276:immunology; D006650:Histocompatibility Testing; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications* / Q000473:pathology / Q000628:therapy; D017708:Leukocyte Transfusion; D008297:Male; D009035:Mothers; D013997:Time Factors; D014181:Transplantation Immunology; D014184:Transplantation, Homologous; D016896:Treatment Outcome
D000949:Histocompatibility Antigens Class II